Pivotal Peptides表示，它提供研究级的替尔泊肽，而MangoRx则在网上销售复合版本。根据诉讼，医疗水疗中心Genesis销售和管理这种药物的复合版本。礼来公司指控Pivotal Peptides在没有任何医疗专业人员处方的情况下，直接向患者销售声称含有替尔泊肽的产品，尽管这些药物的广告是用于研究目的。这些诉讼是在印第安纳州、德克萨斯州和华盛顿州的联邦和州法院提起的，指控每个被告进行虚假广告和促销。Eli Lilly and Co announced on Monday that it has sued three medical spas and online retailers, claiming that the products they sell contain teriparatide.
According to Zhitong Finance and Economics, Eli Lilly and Co (LLY, USA) stated on Monday that it has sued three medical spas and online retailers, alleging that the products they sell contain tirzepatide. Tirzepatide is the main component of Eli Lilly and Co's popular weight-loss drug Zepbound.
These three new lawsuits are against Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine of Nevada. This is the first lawsuit related to generic tirzepatide since the FDA removed tirzepatide from the list of scarce drugs earlier this month. Lilly stated that these lawsuits are not dependent on whether tirzepatide is removed from the list, and can be filed regardless of the supply issues being resolved.
Pivotal Peptides states that it provides research-grade tirzepatide, while MangoRx sells a compound version online. According to the lawsuit, the medical spa Genesis sells and manages this compound version of the drug. Eli Lilly and Co accuses Pivotal Peptides of directly selling products containing tirzepatide to patients without any medical professionals' prescriptions, even though the drugs are advertised for research purposes. These lawsuits were filed in the federal and state courts of Indiana, Texas, and Washington, accusing each defendant of false advertising and promotion.
Before filing the lawsuit, Eli Lilly and Co sent a cease and desist letter to Pivotal Peptides. According to the pharmaceutical company's lawsuit, after Eli Lilly and Co sent a cease and desist letter to Pivotal Peptides, the supplier changed its website claiming maintenance, and shifted its operation to sales through email, social media, and word of mouth.
Eli Lilly and Co has sued more than twenty medical spas, health centers, and compound pharmacies for claiming that the products they sell contain tirzepatide, which is also approved for treating type 2 diabetes under the brand name Mounjaro. In recent filings, Lilly stated that MangoRx is selling an oral tirzepatide named Trim, despite lacking any studies showing the formulation is safe and effective. So far, the FDA has only approved tirzepatide as an injectable treatment drug.
Eli Lilly and Co stated that Genesis claims to sell a compound teriparatide containing vitamin B12, and this combination is 'untested, unconfirmed, and poses unreasonable risks to consumers.'
Eli Lilly and Co is seeking a court order to prohibit suppliers from selling pharmaceuticals claiming to contain tesamorelin, requesting an undisclosed amount of compensation.
An eli lilly and co spokesperson said: "Eli Lilly Company takes these actions to protect American consumers from direct patient safety risks, defendants make false claims in terms of efficacy or safety and mislead consumers on clinical data used to support these claims."
